Synergy Pharmaceuticals (SGYP +0.7%) files a supplemental New Drug Application (sNDA) with the FDA seeking approval of TRULANCE (plecanatide) to treat adults with irritable bowel syndrome with ...

MONTREAL, QUEBEC--(Marketwired - Jan 9, 2014) - Synergy Acquisition Corp. (the "Corporation") (CSE:QMP) is pleased to announce that the NI 43-101 technical report for its Lullwitz-Kaeppeli property ...

Fan Who Wore 'Inappropriate' Outfit To College Football Game Arrested Marjorie Taylor Greene Tells ’60 Minutes’ That ‘It Would Shock People’ to Hear How Congressional Republicans Talk About Trump in ...

Global Synergy Acquisition, a blank check company targeting technology services, filed on Friday with the SEC to raise up to $225 million in an initial public offering. The New York, NY-based company ...

Synergy CHC (NASDAQ:SNYR) filed to sell 1.28 million shares of common stock. This prospectus is not an offer to sell these securities. Filing Synergy CHC secures retail deals with McKesson Canada and ...

Synergy Pharmaceuticals Inc.(Nasdaq: SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced the planned spin-off of its FV-100 assets into a separate ...

Synergy Pharmaceuticals Inc, a developer of gastrointestinal therapies, filed for bankruptcy on Wednesday with a deal to be acquired by Canadian health products maker Bausch Health Companies Inc for ...

A monthly check for $4,873 might sound great, but it might not be everything it's cracked up to be. Sky-high dividend yields suggest these stocks are too hot to handle, but billionaires bought ...